According to the National Institute for Health and Clinical Excellence (NICE), eribulin is NOT recommended for patients with locally advanced or metastatic breast cancer, particularly in cases where a patient's symptoms have worsened after chemotherapy. According to NICE, "eribulin does not provide enough benefit to patients to justify its high cost."
Consult the
NICE Technology Appraisal TA 250 for more information.